乐普生物-B（02157）：MRG006A联合疗法IND获批，有望推动肝癌精准治疗

Investment Rating - The report initiates coverage with a "Buy" rating for Lepu Biopharma (2157.HK) [4] Core Insights - Lepu Biopharma's ADC drug MRG006A has received approval for clinical trials, marking a significant step towards precision treatment for liver cancer [1] - MRG006A is the first GPC3-targeted ADC to enter clinical trials globally, with potential to address unmet clinical needs in liver cancer treatment [1][2] - The company has a strong pipeline with multiple ADC products and has successfully commercialized two drugs, indicating a leading position in the ADC market [3] Financial Projections - Expected revenues for Lepu Biopharma are projected to be 368 million RMB in 2024, 944 million RMB in 2025, and 1.428 billion RMB in 2027, with growth rates of 63.2%, 156.5%, and 44.4% respectively [5] - The net profit attributable to the parent company is forecasted to be -411 million RMB in 2024, -35 million RMB in 2025, and 89 million RMB in 2027, indicating a turnaround by 2027 [5] - Earnings per share (EPS) are expected to improve from -0.23 RMB in 2024 to 0.05 RMB in 2027 [5] Product Pipeline and Market Position - Lepu Biopharma's product pipeline includes 8 clinical candidates, with 6 being ADC products, showcasing a robust focus on innovative therapies [3] - The company has successfully licensed two ADCs internationally, with significant financial agreements, indicating strong market confidence [3] - MRG006A and MRG007 are developed based on the next-generation Hi-TOPi ADC platform, which is expected to enhance the company's value [3]